Pfizer (PFE) Other Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has 17 years of Other Accumulated Expenses data on file, last reported at $20.1 billion in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $20.1 billion, changed 0.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.1 billion (changed 0.46% YoY), and the FY2025 annual result was $19.4 billion, down 1.46% from the prior year.
• Other Accumulated Expenses climbed to $20.1 billion in Q1 2026 per PFE's latest filing, from $19.4 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $24.6 billion in Q2 2022 and troughed at $16.1 billion in Q3 2023.
• A 5-year average of $19.8 billion and a median of $19.7 billion in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 92.08% in 2022, then plunged 32.49% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $22.6 billion in 2022, then decreased by 9.0% to $20.5 billion in 2023, then retreated by 3.98% to $19.7 billion in 2024, then slipped by 1.46% to $19.4 billion in 2025, then increased by 3.48% to $20.1 billion in 2026.
• Business Quant data shows PFE's Other Accumulated Expenses at $20.1 billion in Q1 2026, $19.4 billion in Q4 2025, and $19.5 billion in Q3 2025.